Synthetic Biologics: Marcum LLP MicroCap Conference (Synthetic Biologics Press Release) - Jun 14, 2014 - "MS: Relapsing-Remitting MS"; "Phase II Results of Trimesta (oral estradiol)"; "Topline results presented at 2014 AAN by Dr. Voskuhl demonstrated: Statistically significant 47% decrease in annualized MS relapse rate at 12 months with Trimesta+Copaxone (p=0.03 / powered for significance level 0.05), 32% decrease in annualized relapse rate at 24 months with Trimesta+Copaxone compared to placebo+Copaxone (p=0.15 / powered for significance level 0.10): Per study protocol, investigators anticipated a 29% decrease in relapse rate at both 12 and 24 months, Clinically significant near-normalization of cognitive scores at 12 months of therapy with Trimesta+Copaxone: Unique neuroprotective effect of oral estriol highly significant to MS community"; "Trimesta+Copaxone was generally well tolerated" "
P2 data • Multiple Sclerosis
|